Europe Radiopharmaceuticals Market
Taille du marché en milliards USD
TCAC :
% 
3,487.24
2023
2030
 Période de prévision |
2024 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
Dollars américains 3,487.24 |
 TCAC |
% |
| Principaux acteurs du marché |
Marché européen des produits radiopharmaceutiques, par type (produits radiopharmaceutiques diagnostiques et produits radiopharmaceutiques thérapeutiques), application (diagnostique et thérapeutique), source (réacteurs nucléaires et cyclotrons), utilisateur final (hôpitaux, centres de diagnostic, instituts de recherche sur le cancer, centres de chirurgie ambulatoire et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché européen des produits radiopharmaceutiques
La prise de conscience croissante des produits radiopharmaceutiques en Europe a accru la demande sur le marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent sur le lancement et l'approbation de divers services au cours de cette période cruciale. En outre, l'amélioration des techniques de développement de médicaments contribue également à la demande croissante de produits radiopharmaceutiques.
Le marché européen des produits radiopharmaceutiques devrait croître en raison de l'augmentation du nombre d'acteurs sur le marché et de la disponibilité de services avancés. Parallèlement, les fabricants se sont engagés dans l'activité de développement pour lancer de nouveaux services sur le marché. La croissance croissante dans le domaine du développement de médicaments stimule encore davantage la croissance du marché. Cependant, des difficultés telles que le manque de protocoles standardisés et le manque de professionnels qualifiés devraient freiner la croissance du marché.
L'augmentation des dépenses de santé consacrées au développement de nouveaux médicaments devrait ouvrir des opportunités au marché. Cependant, le recours croissant à des traitements alternatifs pourrait remettre en cause la croissance du marché.
Data Bridge Market Research analyse que le marché européen des produits radiopharmaceutiques devrait atteindre une valeur de 3 487,24 millions USD d'ici 2030, à un TCAC de 5,9 % au cours de la période de prévision 2023-2030.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Année historique |
2021 (personnalisable de 2015 à 2020) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Type (radiopharmaceutiques diagnostiques et thérapeutiques), application (diagnostique et thérapeutique), source (réacteurs nucléaires et cyclotrons), utilisateur final (hôpitaux, centres de diagnostic, instituts de recherche sur le cancer, centres de chirurgie ambulatoire et autres) |
|
Pays couverts |
Allemagne, Royaume-Uni, France, Italie, Espagne, Belgique, Pologne, Russie, Norvège, Turquie, Autriche, Irlande, Hongrie, Pays-Bas, Suisse et reste de l'Europe |
|
Acteurs du marché couverts |
Cardinal Health, Advanced Accelerator Applications, une société Novartis, Lantheus, CURIUM, Jubilant Radiopharma, une société Jubilant Pharmova, China isotope & Radiation Corporation, Siemens Healthcare GmbH, Bracco, Eckert & Ziegler, SHINE Technologies, LLC, IBA Worldwide, Institute of Isotopes, entre autres |
Définition du marché européen des produits radiopharmaceutiques
Un produit radiopharmaceutique contient une substance radioactive associée à un ou plusieurs ingrédients destinés à diagnostiquer, à déterminer le stade d'une maladie, à surveiller un traitement ou à fournir une thérapie. Les produits radiopharmaceutiques comprennent un groupe d'agents radioactifs utilisés pour des interventions diagnostiques ou thérapeutiques. Il s'agit des produits pharmaceutiques qui incorporent un radionucléide. La plupart des produits radiopharmaceutiques sont une combinaison d'un nucléide radioactif ou d'un radionucléide et d'une molécule ou d'un médicament biologiquement actif qui agit comme un vecteur et détermine la localisation et la biodistribution.
Dynamique du marché européen des produits radiopharmaceutiques
Cette section traite de la compréhension des moteurs, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :
Conducteur
- La demande croissante de produits radiopharmaceutiques à des fins diagnostiques et cliniques
Les produits radiopharmaceutiques sont devenus essentiels pour aider au diagnostic des organes et au traitement des troubles pathologiques. Ils sont utilisés en imagerie diagnostique et en radiothérapie. Les produits radiopharmaceutiques diagnostiques n'ont aucun effet pharmacologique et leur administration n'est pas non plus considérée comme associée à des effets secondaires cliniques pertinents.
Le nombre de radiopharmaceutiques utilisés en clinique augmente rapidement, permettant ainsi à la communauté médicale d'accéder à des informations détaillées sur les caractéristiques des différents types de tumeurs. Les radionucléides gagnent également en importance en fournissant des traitements palliatifs et curatifs pour un nombre croissant de maladies malignes.
Opportunité
- L' augmentation des dépenses de recherche et développement des produits radiopharmaceutiques
Les progrès technologiques comprennent l'amélioration de la stabilité et de la résistance des produits pharmaceutiques traditionnels. Les sociétés biotechnologiques et pharmaceutiques investissent en permanence dans la recherche et le développement pour offrir des services innovants en matière de diagnostic et de médicaments aux clients et renforcer leur présence sur le marché. Les produits radiopharmaceutiques jouent un rôle dynamique dans le développement clinique. Alors que l'industrie du diagnostic est dans un état de fluctuation constante en raison de la mise en œuvre de nouvelles technologies sur le marché, les industries pharmaceutiques et biotechnologiques continuent de croître en raison de l'augmentation des investissements dans les sociétés radiopharmaceutiques ainsi que des fusions et acquisitions et de l'adoption d'innovations dans les technologies d'imagerie pour soutenir les essais cliniques pour diverses maladies.
Les dépenses croissantes en recherche et développement dans les entreprises pharmaceutiques et biotechnologiques constituent une opportunité pour la croissance du marché européen des produits radiopharmaceutiques.
Contraintes /Défis
- Réglementation stricte pour les produits radiopharmaceutiques
Les produits radiopharmaceutiques sont des agents utilisés pour diagnostiquer certains problèmes médicaux ou traiter certaines maladies. Par conséquent, les différents types de réglementations gouvernementales pour le lancement d'un produit sur le marché constituent un obstacle majeur. Chaque pays a ses propres réglementations et dispose de différents organismes pour les procédures réglementaires. Des politiques strictes en matière de réglementation et d'approbation des produits devraient entraver le développement du marché des produits radiopharmaceutiques.
Les réglementations strictes imposées par les autorités gouvernementales sont nécessaires pour préserver la réputation de l'entreprise, éviter que les produits ne soient peu fiables et accroître la confiance des consommateurs. Il existe plusieurs étapes d'investissement et de tests pour obtenir l'approbation de l'autorité réglementée pour un nouveau médicament, qui comprend plusieurs phases et chaque phase a des exigences réglementaires différentes.
L'organisation qui mène l'essai doit se conformer à la documentation requise par l'autorité réglementaire spécifique du pays concerné et doit être sûre et légale conformément aux politiques et à la juridiction du pays.
Cependant, les directives réglementaires strictes pour réguler les produits radiopharmaceutiques sur le marché peuvent entraver la croissance du marché, et les retraits du médicament du marché en raison d'une réglementation complexe peuvent avoir un impact négatif sur le marché, ce qui devrait freiner la croissance du marché.
- Coût élevé du développement et de la mise en œuvre des produits radiopharmaceutiques
Les produits radiopharmaceutiques jouent un rôle important dans les établissements de santé, en garantissant sécurité et efficacité dans les entreprises pharmaceutiques et biotechnologiques. Ils présentent à la fois d'excellentes propriétés et certains inconvénients. Les produits radiopharmaceutiques devraient croître en raison des progrès technologiques. Cependant, plusieurs obstacles peuvent empêcher le marché de réaliser son plein potentiel, car les produits radiopharmaceutiques sont coûteux à développer et à mettre en œuvre, et le marché peut ne pas se développer rapidement. Ainsi, les coûts de développement et de mise en œuvre plus élevés et les exigences en matière de surfaces adaptées limitent la croissance du marché, ce qui entraîne des coûts d'infrastructure et d'exploitation supplémentaires.
Développements récents
- En octobre 2023, IBA a lancé AKURACY, une solution intégrée d'imagerie cardiaque pour animaux de compagnie, à chaque congrès à Barcelone. La société estime et affirme qu'il s'agit d'une solution intégrée unique pour l'imagerie de perfusion myocardique pour animaux de compagnie.
- En avril 2023, Lantheus et POINT Biopharma ont annoncé que la FDA accordait une désignation accélérée pour ¹⁷⁷Lu-PNT2002 pour le traitement du cancer de la prostate métastatique résistant à la castration. La société a déclaré que la thérapie par radioligands devient rapidement un autre pilier du traitement du cancer.
Portée du marché européen des produits radiopharmaceutiques
Le marché européen des produits radiopharmaceutiques est segmenté en quatre segments notables tels que le type, l'application, la source et l'utilisateur final. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et les différences dans vos marchés cibles.
Taper
- Produits radiopharmaceutiques diagnostiques
- Produits radiopharmaceutiques thérapeutiques
Sur la base du type, le marché est segmenté en produits radiopharmaceutiques diagnostiques et produits radiopharmaceutiques thérapeutiques.
Application
- Diagnostique
- Thérapeutique
En fonction des applications, le marché est segmenté en diagnostic et en thérapeutique.
Source
- Réacteurs nucléaires
- Cyclotrons
Sur la base de la source, le marché est segmenté en réacteurs nucléaires et cyclotrons.
Utilisateur final
- Hôpitaux
- Centres de diagnostic
- Instituts de recherche sur le cancer
- Centres de chirurgie ambulatoire
- Autres
Sur la base de l'utilisateur final, le marché est segmenté en hôpitaux, centres de diagnostic, instituts de recherche sur le cancer, centres de chirurgie ambulatoire et autres.
Analyse/perspectives régionales du marché européen des produits radiopharmaceutiques
Le marché européen des produits radiopharmaceutiques est segmenté en quatre segments notables tels que le type, l’application, la source et l’utilisateur final.
Les pays couverts dans ce rapport de marché sont l'Allemagne, le Royaume-Uni, la France, l'Italie, l'Espagne, la Belgique, la Pologne, la Russie, la Norvège, la Turquie, l'Autriche, l'Irlande, la Hongrie, les Pays-Bas, la Suisse et le reste de l'Europe.
L'Allemagne devrait dominer le marché en raison de l'augmentation des investissements dans le secteur de la santé, ce qui devrait stimuler la croissance du marché. L'Allemagne devrait dominer la région Europe en raison de l'augmentation des progrès technologiques dans les produits de santé et de traitement.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs douaniers d'import-export sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des produits radiopharmaceutiques en Europe
Le paysage concurrentiel du marché européen des produits radiopharmaceutiques fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.
Certains des principaux acteurs du marché opérant sur le marché européen des produits radiopharmaceutiques sont Cardinal Health, Advanced Accelerator Applications, A Novartis Company, Lantheus, CURIUM, Jubilant Radiopharma A Jubilant Pharmova Company, China isotope & Radiation Corporation., Siemens Healthcare GmbH, Bracco, Eckert & Ziegler, SHINE Technologies, LLC, IBA Worldwide, Institute of Isotopes, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE RADIOPHARMACEUTICALS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PIPELINE ANALYSIS
4.4 PATENT ANALYSIS
4.5 DRUG TREATMENT RATE BY MATURED MARKETS
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.7 PATIENT FLOW DIAGRAM
4.8 KEY PRICING STRATEGIES
4.9 KEY PATIENT ENROLLMENT STRATEGIES
5 LIST OF CYCLOTRONS
5.1 EUROPE
6 REGULATORY SCENARIO
6.1 EUROPE
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE
7.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS
7.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS
7.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS
7.3 OPPORTUNITIES
7.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS
7.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION
7.4 CHALLENGES
7.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS
7.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE
8 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS
8.2.1 PET RADIOPHARMACEUTICALS
8.2.1.1 F-18
8.2.1.2 RU-82
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS
8.2.2 SPECT RADIOPHARMACEUTICALS
8.2.2.1 TECHNETIUM-99M
8.2.2.2 GALLIUM-67
8.2.2.3 IODINE-123
8.2.2.4 THALLIUM-201
8.2.2.5 OTHER SPECT ISOTOPES
8.3 THERAPEUTIC RADIOPHARMACEUTICALS
8.3.1 BRACHYTHERAPY ISOTOPES
8.3.1.1 IODINE-125
8.3.1.2 PALLADIUM-103
8.3.1.3 CESIUM-131
8.3.1.4 IRIDIUM-192
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES
8.3.2 BETA EMITTERS
8.3.2.1 IODINE-131
8.3.2.2 LUTHETIUM-177
8.3.2.3 SAMARIUM-153
8.3.2.4 YTTRIUM-90
8.3.2.5 RHENIUM-186
8.3.2.6 OTHER BETA EMITTERS
8.3.3 ALPHA EMITTERS
8.3.3.1 RA-223
8.3.3.2 OTHERS
9 EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 DIAGNOSTIC
9.2.1 PET
9.2.1.1 ONCOLOGY
9.2.1.2 CARDIOLOGY
9.2.1.3 NEUROLOGY
9.2.1.4 OTHER PET APPLICATION
9.2.2 SPECT
9.2.2.1 CARDIOLOGY
9.2.2.2 BONE SCANS
9.2.2.3 THYROID APPLICATIONS
9.2.2.4 PULMONARY SCANS
9.2.2.5 OTHER SPECT APPLICATION
9.3 THERAPEUTIC
9.3.1 THYROID INDICATIONS
9.3.2 BONE METASTASIS
9.3.3 LYMPHOMA
9.3.4 ENDOCRINE TUMORS
9.3.5 OTHER INDICATIONS
10 EUROPE RADIOPHARMACEUTICALS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 NUCLEAR REACTORS
10.3 CYCLOTRONS
11 EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 DIAGNOSTIC CENTERS
11.4 CANCER RESEARCH INSTITUTES
11.5 AMBULATORY SURGICAL CENTERS
11.6 OTHERS
12 EUROPE RADIOPHARMACEUTICAL MARKET
12.1 EUROPE
12.1.1 GERMANY
12.1.2 U.K.
12.1.3 FRANCE
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 BELGIUM
12.1.7 POLAND
12.1.8 RUSSIA
12.1.9 NORWAY
12.1.10 TURKEY
12.1.11 AUSTRIA
12.1.12 IRELAND
12.1.13 HUNGARY
12.1.14 NETHERLANDS
12.1.15 SWITZERLAND
12.1.16 REST OF EUROPE
13 COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 CARDINAL HEALTH
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENT
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 LANTHEUS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 CURIUM
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 GENERAL ELECTRIC COMPANY
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 BRACCO
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 CHINA ISOTOPE & RADIATION CORPORATION
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ECKERT & ZIEGLER
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 IBA WORLDWIDE
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 INSTITUTE OF ISOTOPES
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 SHINE TECHNOLOGIES, LLC
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 SIEMENS HEALTHCARE GMBH
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 3 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 11 EUROPE PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 15 EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 16 EUROPE RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 17 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 18 EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 21 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 22 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 23 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 24 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 25 EUROPE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 26 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 27 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 28 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 29 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 30 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 31 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 32 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 33 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 34 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 35 EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 36 EUROPE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 41 EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 42 GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 43 GERMANY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 44 GERMANY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 45 GERMANY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 46 GERMANY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 47 GERMANY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 48 GERMANY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 49 GERMANY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 50 GERMANY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 51 GERMANY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 52 GERMANY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 53 GERMANY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 54 GERMANY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 55 GERMANY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 56 GERMANY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 57 GERMANY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 58 GERMANY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 59 GERMANY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 60 GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 61 GERMANY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 62 GERMANY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 63 GERMANY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 64 GERMANY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 65 GERMANY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 66 GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 67 U.K. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 68 U.K. DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 69 U.K. PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 70 U.K. PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 71 U.K. PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 72 U.K. SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 73 U.K. SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 74 U.K. SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 75 U.K. THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.K. BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.K. BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 78 U.K. BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 79 U.K. BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 80 U.K. BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 81 U.K. BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 82 U.K. ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 U.K. ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 84 U.K. ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 85 U.K. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 86 U.K. DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 U.K. PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 88 U.K. SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 89 U.K. THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 90 U.K. RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 91 U.K. RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 93 FRANCE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 94 FRANCE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 95 FRANCE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 96 FRANCE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 97 FRANCE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 FRANCE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 99 FRANCE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 100 FRANCE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 FRANCE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 FRANCE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 103 FRANCE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 104 FRANCE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 105 FRANCE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 106 FRANCE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 107 FRANCE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 108 FRANCE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 109 FRANCE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 110 FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 111 FRANCE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 112 FRANCE PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 113 FRANCE SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 114 FRANCE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 115 FRANCE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 116 FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 117 ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 118 ITALY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 ITALY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 120 ITALY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 121 ITALY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 122 ITALY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 123 ITALY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 124 ITALY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 125 ITALY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 126 ITALY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 127 ITALY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 128 ITALY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 129 ITALY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 130 ITALY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 131 ITALY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 132 ITALY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 133 ITALY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 134 ITALY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 135 ITALY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 136 ITALY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 137 ITALY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 ITALY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 ITALY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 ITALY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 141 ITALY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 142 SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 143 SPAIN DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 144 SPAIN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 145 SPAIN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 146 SPAIN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 147 SPAIN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 148 SPAIN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 149 SPAIN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 150 SPAIN THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 151 SPAIN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 152 SPAIN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 153 SPAIN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 154 SPAIN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 155 SPAIN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 156 SPAIN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 157 SPAIN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 158 SPAIN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 159 SPAIN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 160 SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 161 SPAIN DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 162 SPAIN PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 163 SPAIN SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 164 SPAIN THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 165 SPAIN RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 166 SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 167 BELGIUM RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 168 BELGIUM DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 169 BELGIUM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 170 BELGIUM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 171 BELGIUM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 172 BELGIUM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 173 BELGIUM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 174 BELGIUM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 175 BELGIUM THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 176 BELGIUM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 177 BELGIUM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 178 BELGIUM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 179 BELGIUM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 180 BELGIUM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 181 BELGIUM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 182 BELGIUM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 183 BELGIUM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 184 BELGIUM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 185 BELGIUM RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 186 BELGIUM DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 187 BELGIUM PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 188 BELGIUM SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 189 BELGIUM THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 190 BELGIUM RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 191 BELGIUM RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 192 POLAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 193 POLAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 194 POLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 195 POLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 196 POLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 197 POLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 198 POLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 199 POLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 200 POLAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 201 POLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 202 POLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 203 POLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 204 POLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 205 POLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 206 POLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 207 POLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 POLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 209 POLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 210 POLAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 211 POLAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 212 POLAND PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 213 POLAND SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 214 POLAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 POLAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 216 POLAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 RUSSIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 218 RUSSIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 219 RUSSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 220 RUSSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 221 RUSSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 222 RUSSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 223 RUSSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 224 RUSSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 225 RUSSIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 226 RUSSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 227 RUSSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 228 RUSSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 229 RUSSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 230 RUSSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 231 RUSSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 232 RUSSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 233 RUSSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 234 RUSSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 235 RUSSIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 236 RUSSIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 237 RUSSIA PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 238 RUSSIA SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 239 RUSSIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 240 RUSSIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 241 RUSSIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 242 NORWAY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 243 NORWAY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 244 NORWAY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 245 NORWAY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 246 NORWAY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 247 NORWAY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 248 NORWAY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 249 NORWAY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 250 NORWAY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 251 NORWAY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 252 NORWAY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 253 NORWAY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 254 NORWAY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 255 NORWAY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 256 NORWAY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 257 NORWAY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 258 NORWAY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 259 NORWAY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 260 NORWAY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 261 NORWAY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 262 NORWAY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 263 NORWAY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 264 NORWAY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 265 NORWAY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 266 NORWAY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 267 TURKEY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 268 TURKEY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 269 TURKEY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 270 TURKEY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 271 TURKEY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 272 TURKEY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 273 TURKEY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 274 TURKEY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 275 TURKEY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 276 TURKEY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 277 TURKEY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 278 TURKEY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 279 TURKEY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 280 TURKEY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 281 TURKEY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 282 TURKEY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 283 TURKEY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 284 TURKEY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 285 TURKEY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 286 TURKEY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 287 TURKEY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 288 TURKEY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 289 TURKEY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 290 TURKEY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 291 TURKEY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 292 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 293 AUSTRIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 294 AUSTRIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 295 AUSTRIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 296 AUSTRIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 297 AUSTRIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 298 AUSTRIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 299 AUSTRIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 300 AUSTRIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 301 AUSTRIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 302 AUSTRIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 303 AUSTRIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 304 AUSTRIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 305 AUSTRIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 306 AUSTRIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 307 AUSTRIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 308 AUSTRIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 309 AUSTRIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 310 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 311 AUSTRIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 312 AUSTRIA PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 313 AUSTRIA SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 314 AUSTRIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 315 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 316 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 317 IRELAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 318 IRELAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 319 IRELAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 320 IRELAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 321 IRELAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 322 IRELAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 323 IRELAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 324 IRELAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 325 IRELAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 326 IRELAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 327 IRELAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 328 IRELAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 329 IRELAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 330 IRELAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 331 IRELAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 332 IRELAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 333 IRELAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 334 IRELAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 335 IRELAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 336 IRELAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 337 IRELAND PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 338 IRELAND SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 339 IRELAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 340 IRELAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 341 IRELAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 342 HUNGARY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 343 HUNGARY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 344 HUNGARY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 345 HUNGARY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 346 HUNGARY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 347 HUNGARY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 348 HUNGARY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 349 HUNGARY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 350 HUNGARY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 351 HUNGARY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 352 HUNGARY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 353 HUNGARY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 354 HUNGARY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 355 HUNGARY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 356 HUNGARY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 357 HUNGARY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 358 HUNGARY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 359 HUNGARY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 360 HUNGARY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 361 HUNGARY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 362 HUNGARY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 363 HUNGARY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 364 HUNGARY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 365 HUNGARY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 366 HUNGARY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 367 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 368 NETHERLANDS DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 369 NETHERLANDS PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 370 NETHERLANDS PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 371 NETHERLANDS PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 372 NETHERLANDS SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 373 NETHERLANDS SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 374 NETHERLANDS SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 375 NETHERLANDS THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 376 NETHERLANDS BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 377 NETHERLANDS BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 378 NETHERLANDS BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 379 NETHERLANDS BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 380 NETHERLANDS BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 381 NETHERLANDS BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 382 NETHERLANDS ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 383 NETHERLANDS ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 384 NETHERLANDS ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 385 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 386 NETHERLANDS DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 387 NETHERLANDS PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 388 NETHERLANDS SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 389 NETHERLANDS THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 390 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 391 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 392 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 393 SWITZERLAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 394 SWITZERLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 395 SWITZERLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 396 SWITZERLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 397 SWITZERLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 398 SWITZERLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 399 SWITZERLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 400 SWITZERLAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 401 SWITZERLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 402 SWITZERLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 403 SWITZERLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 404 SWITZERLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 405 SWITZERLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 406 SWITZERLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP IN MBQ)
TABLE 407 SWITZERLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 408 SWITZERLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 409 SWITZERLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 410 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 411 SWITZERLAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 412 SWITZERLAND PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 413 SWITZERLAND SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 414 SWITZERLAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 415 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 416 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 417 REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE RADIOPHARMACEUTICALS: SEGMENTATION
FIGURE 2 EUROPE RADIOPHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE RADIOPHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE RADIOPHARMACEUTICALS MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE RADIOPHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE RADIOPHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE RADIOPHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE RADIOPHARMACEUTICALS MARKET: MARKET TYPE COVERAGE GRID
FIGURE 9 EUROPE RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 10 THE RISING PREVALENCE OF CHRONIC DISEASES IS EXPECTED TO DRIVE THE EUROPE RADIOPHARMACEUTICALS MARKET IN THE FORECAST PERIOD
FIGURE 11 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE RADIOPHARMACEUTICALS MARKET IN 2023 & 2030
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE RADIOPHARMACEUTICALS MARKET
FIGURE 13 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, 2022
FIGURE 14 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 15 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 16 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 17 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2022
FIGURE 18 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 19 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 20 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 21 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2022
FIGURE 22 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2023-2030 (USD MILLION)
FIGURE 23 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, CAGR (2023-2030)
FIGURE 24 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 25 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, 2022
FIGURE 26 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 27 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 28 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 EUROPE RADIOPHARMACEUTICALS MARKET: SNAPSHOT (2022)
FIGURE 30 EUROPE RADIOPHARMACEUTICALS MARKET: BY COUNTRY (2022)
FIGURE 31 EUROPE RADIOPHARMACEUTICALS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 32 EUROPE RADIOPHARMACEUTICALS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 33 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE (2023-2030)
FIGURE 34 EUROPE RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
